Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Merck & Co., Inc.'s quarterly P/E stands at 22.1x, up 31.6% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has compressed 45.9% YoY to 6.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 17.00 | 22.11 | 9.04 | 11.24 | 11.16 | 16.80 | 22.90 | 14.46 | 17.64 | — | 13.84 | — | 23.96 |
| — | +31.6% | -60.5% | -22.3% | -36.7% | — | +65.5% | — | -26.4% | — | -17.7% | — | +98.6% | |
| P/S Ratio | 4.73 | 3.99 | 3.03 | 3.15 | 3.66 | 4.04 | 4.33 | 4.89 | 5.32 | 4.76 | 4.11 | 4.87 | 4.68 |
| — | -1.3% | -29.9% | -35.6% | -31.2% | -15.0% | +5.5% | +0.3% | +13.6% | -6.9% | +12.2% | +22.8% | +43.1% | |
| P/B Ratio | 5.98 | 5.05 | 4.04 | 4.05 | 4.69 | 5.45 | 6.48 | 7.22 | 8.30 | 7.40 | 6.35 | 7.56 | 5.79 |
| — | -7.4% | -37.6% | -43.8% | -43.5% | -26.3% | +2.0% | -4.6% | +43.5% | +20.5% | +29.1% | +41.5% | +13.8% | |
| P/FCF | — | — | 7.67 | 19.66 | 48.46 | 25.15 | 8.48 | 16.25 | 37.65 | — | 9.62 | 26.74 | 204.37 |
| — | — | -9.6% | +21.0% | +28.7% | — | -11.8% | -39.2% | -81.6% | — | -21.4% | +46.6% | +1383.3% | |
| EV / EBITDA | 9.89 | 6.78 | 7.55 | 8.48 | 9.00 | 12.53 | 15.09 | 11.76 | 13.51 | — | 10.47 | — | 15.24 |
| — | -45.9% | -50.0% | -27.9% | -33.3% | — | +44.2% | — | -11.4% | — | -11.0% | — | +77.6% | |
| EV / EBIT | 11.47 | 11.07 | 8.23 | 10.67 | 10.19 | 15.44 | 17.65 | 13.51 | 15.25 | — | 12.14 | — | 18.78 |
| — | -28.3% | -53.4% | -21.1% | -33.2% | — | +45.4% | — | -18.8% | — | -22.0% | — | +65.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Merck & Co., Inc.'s operating margin was 53.3% in Q4 2025, up 15.3 pp QoQ and up 25.4 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 41.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 22.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.5% | 92.7% | 77.7% | 77.5% | 78.0% | 75.5% | 75.5% | 76.8% | 77.6% | 73.3% | 73.3% | 73.2% | 72.9% |
| — | +22.8% | +2.9% | +1.0% | +0.5% | +3.1% | +3.0% | +4.8% | +6.4% | +1.8% | -0.6% | +3.0% | +10.2% | |
| Operating Margin | 41.2% | 53.3% | 37.9% | 35.1% | 38.2% | 27.8% | 23.9% | 38.0% | 36.5% | -11.7% | 36.8% | -33.3% | 26.3% |
| — | +91.4% | +58.6% | -7.6% | +4.7% | +337.7% | -35.0% | +214.1% | +39.0% | -146.4% | +34.0% | -196.0% | -25.7% | |
| Net Margin | 28.1% | 18.1% | 33.5% | 28.0% | 32.7% | 24.0% | 19.0% | 33.9% | 30.2% | -8.4% | 29.7% | -39.7% | 19.5% |
| — | -24.6% | +76.7% | -17.3% | +8.3% | +385.9% | -36.2% | +185.2% | +55.0% | -138.4% | +36.9% | -247.0% | -28.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 37.1% | 5.7% | 11.5% | 9.1% | 10.7% | 8.2% | 7.2% | 13.0% | 12.2% | -3.1% | 11.9% | -14.0% | 6.1% |
| — | -30.7% | +60.1% | -30.0% | -12.2% | +365.0% | -39.6% | +193.0% | +101.0% | -146.6% | +60.3% | -249.1% | -44.2% | |
| ROA | — | — | 4.7% | 3.8% | 4.4% | 3.2% | 2.7% | 5.0% | 4.5% | -1.1% | 4.5% | -5.6% | 2.6% |
| — | — | +70.7% | -23.8% | -2.4% | +377.7% | -38.9% | +188.7% | +72.3% | -141.2% | +48.2% | -252.6% | -35.9% | |
| ROIC | 32.6% | 10.3% | 6.5% | 5.5% | 6.1% | 4.7% | 4.3% | 6.6% | 6.3% | -1.9% | 6.4% | -5.5% | 4.3% |
| — | +120.7% | +50.0% | -16.5% | -3.9% | +344.9% | -32.5% | +221.2% | +48.2% | -147.1% | +34.2% | -192.9% | -34.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.80 | 0.72 | 0.72 | 0.83 | 0.86 | 0.87 | 0.85 | 0.96 | 0.84 | 0.95 | 0.66 |
| — | — | -6.9% | -16.6% | -15.0% | -14.4% | +1.4% | -9.1% | +29.1% | +38.8% | +23.5% | +30.3% | -15.6% | |
| Debt / EBITDA | — | — | 5.37 | 5.31 | 4.95 | 6.90 | 7.38 | 5.20 | 5.07 | — | 5.06 | — | 6.41 |
| — | — | -27.2% | +2.0% | -2.4% | — | +45.7% | — | -20.8% | — | -15.7% | — | +35.9% | |
| Current Ratio | — | — | 1.66 | 1.42 | 1.41 | 1.36 | 1.36 | 1.47 | 1.25 | 1.25 | 1.38 | 1.28 | 1.44 |
| — | — | +21.8% | -2.9% | +12.6% | +9.0% | -1.4% | +14.4% | -13.2% | -15.0% | -5.2% | -7.6% | +3.3% | |
| Quick Ratio | — | — | 1.44 | 1.17 | 1.16 | 1.15 | 1.15 | 1.22 | 0.99 | 1.00 | 1.12 | 1.03 | 1.19 |
| — | — | +24.5% | -3.9% | +17.2% | +14.4% | +3.1% | +18.5% | -16.6% | -18.3% | -8.0% | -10.4% | +4.6% | |
| Interest Coverage | — | — | 20.04 | 18.20 | 18.97 | 13.26 | 12.07 | 19.77 | 19.01 | -5.53 | 18.52 | -18.09 | 15.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonMerck & Co., Inc.'s current P/E is 17.0x. The average P/E over the last 4 quarters is 13.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Merck & Co., Inc.'s current operating margin is 41.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Merck & Co., Inc.'s business trajectory between earnings reports.